Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SOPHiA GENETICS (SOPH) Equity Average (2020 - 2025)

SOPHiA GENETICS's Equity Average history spans 6 years, with the latest figure at -$69.4 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 26.4% to -$69.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$69.4 million, a 26.4% decrease, with the full-year FY2025 number at -$70.7 million, changed 0.01% from a year prior.
  • Equity Average hit -$69.4 million in Q4 2025 for SOPHiA GENETICS, down from -$10.0 million in the prior quarter.
  • Over the last five years, Equity Average for SOPH hit a ceiling of $12.3 million in Q2 2022 and a floor of -$80.5 million in Q4 2022.
  • Historically, Equity Average has averaged -$30.5 million across 5 years, with a median of -$33.0 million in 2021.
  • The widest YoY moves for Equity Average: up 156.44% in 2022, down 90.67% in 2022.
  • Tracing SOPH's Equity Average over 5 years: stood at -$63.0 million in 2021, then dropped by 27.74% to -$80.5 million in 2022, then rose by 16.79% to -$67.0 million in 2023, then grew by 17.98% to -$54.9 million in 2024, then dropped by 26.4% to -$69.4 million in 2025.
  • Business Quant data shows Equity Average for SOPH at -$69.4 million in Q4 2025, -$10.0 million in Q3 2025, and $11.2 million in Q2 2025.